Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AFA 281

Next Previous
Drug Profile

AFA 281

Alternative Names: AFA-281

Latest Information Update: 12 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AfaSci
  • Class Analgesics; Anti-inflammatories
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammatory pain; Neuropathic pain

Most Recent Events

  • 06 Dec 2024 Afasci plans a phase I trial for Alcohol related disorders (In volunteers) in January 2025 (PO) (NCT06719908)
  • 29 Nov 2024 Afasci Inc plans a phase IIa trial for Alcohol-related-disorders in USA (PO) (NCT06710431)
  • 21 Oct 2024 Afasci plans to initiate a phase II trial for Lumbosacral Radiculopathy (PO) (NCT06649747)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top